Form 4: Core Scientific Exec Sells Shares Under 10b5-1 Plan

Todd Duchene, Chief Legal and Administrative Officer of Core Scientific, Inc., reported the sale of 9,900 shares of common stock for $20.8499 per share and 100 shares for $21.53 per share, executed under a pre-arranged Rule 10b5-1 trading plan.

Summary

• Todd Duchene, Chief Legal and Administrative Officer of Core Scientific, Inc. (CORZ), has reported transactions involving the sale of common stock.
• The sales occurred on May 4, 2026.
• A total of 9,900 shares were sold at a weighted average price of $20.8499, with individual sale prices ranging from $20.49 to $21.39.
• An additional 100 shares were sold at $21.53.
• These transactions were conducted under a Rule 10b5-1 trading plan adopted by Mr. Duchene on December 5, 2025, which is designed to comply with affirmative defense conditions for insider trading.
• Following these transactions, Mr. Duchene beneficially owns 1,980,348 shares of common stock.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing. While an executive selling shares can be a negative signal, the execution under a Rule 10b5-1 plan mitigates concerns about insider trading and suggests a pre-planned financial management strategy rather than a reaction to adverse company information.

Positives

• The transactions were executed under a Rule 10b5-1 plan, indicating adherence to pre-determined trading strategies and compliance with insider trading regulations.
• The sales occurred at prices generally above $20, suggesting a stable or appreciating stock value at the time of the transactions.

Negatives

• The reporting person, an executive officer, sold a portion of their holdings, which could be perceived negatively by the market, although it was done under a pre-planned strategy.

Risks

• The filing does not explicitly mention any new risks. However, the sale of shares by an executive could be interpreted by some investors as a lack of confidence in future price appreciation, despite the Rule 10b5-1 plan.

Future Outlook

The filing itself does not contain forward-looking statements or guidance. The Rule 10b5-1 plan indicates a pre-determined strategy for future sales, but the specific details of future sales are not disclosed.

Management Comments

• The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 5, 2025.
• The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.49 to $21.39, inclusive.
• The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range.

Industry Context

StockSavvy.ai notes that Form 4 filings are standard for reporting insider transactions. The use of a Rule 10b5-1 plan by Core Scientific's Chief Legal and Administrative Officer is a common practice for executives to diversify their holdings or manage personal finances while mitigating concerns about insider trading. The specific prices indicate a trading range within the current market for CORZ.

Stakeholder Impact

• Shareholders: May interpret the sale as a negative signal, although the Rule 10b5-1 plan provides a degree of reassurance regarding compliance.
• Employees: Similar to shareholders, the impact depends on their perception of executive confidence.
• Creditors/Suppliers: Unlikely to be directly impacted by this specific insider transaction.
• Management: Demonstrates adherence to established corporate governance practices for personal financial management.

Next Steps

• The Rule 10b5-1 plan may continue to result in future sales of Core Scientific stock by the reporting person, depending on its terms and market conditions.
• The company is obligated to provide further information upon request regarding the specific prices of shares sold within the reported range.

Key Dates

Keywords

Core Scientific, CORZ, Form 4, Insider Trading, Rule 10b5-1, Stock Sale, Todd Duchene, Beneficial Ownership, Securities Exchange Act